Clinical trials: Glial Tumor
Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT06410248
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Northwestern University
Glioblastoma
Characterization of the Blood-Brain Barrier in High-Grade Glioma Through Immunohistochemical, Transcriptional, Fluorescein and Radiological Analyses
This prospective study aims to characterize blood brain barrier (BBB) disruption in patients with newly diagnosed glioblastoma multiforme undergoing surgical resection.
- Trial name
- NCT07731555
- Testing
- Multimodal Blood Brain Barrier Assessment
- Where
- Ireland
- Volunteers
- 100 people
- Sponsor
- Patrick Morris
Brain and Central Nervous System Tumors, Metastatic Cancer
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00784914
- Testing
- temsirolimus, pharmacological study, cytokine levels
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Glioblastoma Multiforme, Glioblastoma
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
This is a prospective, single-arm, two stages, open-label, pilot study to investigate the efficacy and safety of FUS add-on bevacizumab (BEV) in rGBM patients.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, Brain Tumor
- Trial name
- NCT04446416
- Testing
- NaviFUS System, Bevacizumab
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- NaviFUS Corporation
Glioblastoma Multiforme
Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
This study will combine the chemotherapy agent temozolomide with the investigational drug SCH66336 (an agent which interferes with new cell growth).
- Trial name
- NCT00038493
- Testing
- Temozolomide and SCH66336
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00006263
- Testing
- filgrastim, carboplatin, temozolomide
- Where
- United States
- Sponsor
- NYU Langone Health
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma
- Trial name
- NCT03210714
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Astrocytoma, Grade III
Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas
Several investigations suggest neural stem cells located in the subventricular region play an active role in promoting or even initiating cortical malignant glioma growth.
- Conditions
- Glioblastoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Malignant Glioma
- Trial name
- NCT03956706
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Sponsor
- Northwell Health
Glioblastoma
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
The goal of this clinical trial is to evaluate the safety and efficacy of PLB1001 Enteric Capsules in the treatment of PTPRZ1-MET fusion gene positive recurrent secondary glioblastoma. The main questions it aims to answer are: 1.
- Trial name
- NCT06105619
- Testing
- PLB1001, Temozolomide, Cisplatin combined with Etoposide
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Recurrent Central Nervous System Neoplasm
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
RATIONALE: Vaccines made from a person's tumor cells and dendritic cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00890032
- Testing
- BTSC mRNA-loaded DCs
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- John Sampson
Glioblastoma Multiforme
NanoTherm In Adjuvant Therapy of Glioblastoma Multiforme
Glioblastoma multiforme (GBM), the most common and malignant primary brain tumor in adults is classified as a World Health Organisation (WHO) grade 4. Surgical removal of the tumor is the primary method of treatment.
- Trial name
- ANCHIALE (NCT06271421)
- Testing
- NanoTherm therapy, Glioma Resection, radiotherapy according to Stupp protocol
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Poznan University of Medical Sciences
Glioblastoma Multiforme, Glioma, Malignant
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
The goal of this clinical trial is to evaluate the safety and efficacy of oncolytic virus TS-2021 in the treatment of recurrent malignant glioma.About 30 eligible participants with recurrent malignant glioma will : Be…
- Trial name
- NCT06585527
- Testing
- TS-2021
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Neurosurgical Institute
Glioma, Malignant
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
The study investigates the occurance of GlioStem positive tumor stem cells in the rescection marigins of hig grade human gliomas
- Trial name
- CeNo2 (NCT05556486)
- Testing
- GlioStem
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska University Hospital
Glioblastoma Multiforme, Glioblastoma
Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.
Relapsed GBMs have a life expectancy of a few months and re-radiation has proven to be safe in terms of toxicity and effective in increasing OS.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioblastoma, Adult
- Trial name
- GLIORAD (NCT04610229)
- Testing
- Hypofractionation guioded by dose painting
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Glioma, Molecular Sequence Variation
Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas
This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology and genetic data.
- Conditions
- Glioma, Molecular Sequence Variation, Genetic Change
- Trial name
- NCT04216537
- Testing
- Glioma groups based on molecular pathology or genetic variation
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Glioblastoma
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
This is a single-center, open-label, dose-range finding Phase I study of hP1A8, a new adjuvant CD200 activation receptor ligand (CD200AR-L), in combination with imiquimod and the GBM6-AD vaccine to treat recurrent glioblastoma…
- Trial name
- NCT04642937
- Testing
- Treatment with hP1A8
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- OX2 Therapeutics
Malignant Glioma
Radiosurgery and Avastin for Recurrent Malignant Gliomas
The purpose of this study is to assess the central nervous system (CNS) toxicity in patients with recurrent malignant gliomas treated with concurrent Avastin and stereotactic radiosurgery (SRS).
- Trial name
- NCT01017250
- Testing
- Stereotactic Radiosurgery (SRS), Bevacizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Glioblastoma
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV
- Trial name
- ATTAC-II (NCT02465268)
- Testing
- pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of Florida
Glioma of Brain
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma
The purpose of this study is to determine if treatment with Topotecan by an alternative method, delivering topotecan directly into brain tumors, is safe and well tolerated.
- Trial name
- NCT03927274
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Brain and Central Nervous System Tumors, Lymphoma
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00053118
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.